This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.


  Mobile version   RSS   Subscribe   Unsubscribe   Archive   Media Kit May. 24, 2012

   Home   Mission/Vision    Membership    Corporate Membership    CME/CEU    JMCM    Contact Us

Click Here to view the Journal of Managed Care Medicine

Online CME/CEU Programs
Multiple Myeloma: An Update on Diagnostic and Treatment Strategies

Advanced Treatment of Osteoporosis in Postmenopausal Women

Decreasing the Cost Burden of Fibromyalgia with Early Diagnosis and Management


Announcing the NAMCP Medical Directors Lung Cancer Resource Center. Click here to visit the website.

Be sure to check out the study results of Verinata's Non-Invasive Prenatal Technology. Click here to view the press release.

Click here to check out the "Latest in Clinical Nutrition" DVD available for purchase now!

Fall Managed Care Forum
November 8-9
Bellagio Hotel

 



 Genomics

Personalized genetic testing not recommended
CNN    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Getting personalized genetic tests that can pinpoint your risk of developing a number of diseases like cancer, diabetes, Alzheimer's or heart disease are not yet "ready for prime time," according to a new recommendation from the American College of Obstetricians and Gynecologists. More

What is the Health Economic Impact of a Non-Invasive Prenatal Test?

Learn About Bridgehead International’s report, authored by Susan Garfield, on the clinical and economic utility of this test in this quarter’s JMCM, entitled “Clinical and Cost Consequences of Incorporating a Novel Non-Invasive Prenatal Test into the Diagnostic Pathway for Fetal Trisomies.


Gene anomaly can predict behavior of prostate cancer
The Clinical Advisor    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The findings of a recent analysis indicate that a specific genomic abnormality found in either benign or malignant prostate tissues is predictive of the clinical outcome of prostate cancer. As researchers state in The American Journal of Pathology, the prediction of prostate cancer clinical outcome remains a major challenge, even with improved early detection by prostate-specific antigen monitoring. More

Genetic testing may not drive up health costs
MedPage Today    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Having the results of a personalized genetic test did not drive patients to utilize potentially costly follow-up healthcare services, a study from the National Institutes of Health found. In the past five years, there have been many new tests marketed to consumers who want to know whether they are genetically susceptible to a range of health conditions and traits, including diabetes and certain types of cancers. More

 Biotech/Diagnostics/Personalized Medicine


Hormone replacement therapy, 10 years after cancer link claims
The Washington Post    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The use of hormone replacement therapy to treat symptoms of menopause has been among the most controversial and confusing issues in the modern medical world. The July 2012 issue of a journal called Climacteric — the journal of the International Menopause Society — is devoted to revisiting the Women's Health Initiative findings 10 years later and seeks to sort out what turned out to be true and untrue about the therapy's impact on women's health. More

Study: Trial vaccine made some more vulnerable to HIV
The New York Times    Share    Share on FacebookTwitterShare on LinkedinE-mail article
A follow-up study on an AIDS vaccine trial that had to be stopped early has confirmed the worst fears of researchers: The vaccine made it more likely, not less, that some men would become infected with HIV. Men who were not circumcised and who had previously caught common colds caused by the same virus used to make the vaccine were two to four times as likely as other men to become infected if they got the vaccine, the study concluded. More


Nursing@
Georgetown


Nursing@Georgetown is a Master’s in Nursing program delivered online by Georgetown University’s renowned School of Nursing & Health Studies.
MORE
Our activities touch many lives
AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company. We discover, develop, manufacture and market prescription medicines for cancer, cardiovascular, gastrointestinal and infection. MORE


 Regenerative Medicine


Scientists turn skin cells into beating heart muscle
Reuters    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Scientists have for the first time succeeded in taking skin cells from patients with heart failure and transforming them into healthy, beating heart tissue that could one day be used to treat the condition. The researchers, based in Haifa, Israel, said there were still many years of testing and refining ahead. But the results meant they might eventually be able to reprogram patients' cells to repair their own damaged hearts. More

Mechanical properties of stem cells can foretell what they will become
PhysOrg    Share    Share on FacebookTwitterShare on LinkedinE-mail article
To become better healers, tissue engineering need a timely and reliable way to obtain enough raw materials: cells that either already are or can become the tissue they need to build. In a new study, Brown University biomedical engineers show the stiffness, viscosity and other mechanical properties of adult stem cells derived from fat, such as liposuction waste, can predict whether they will turn into bone, cartilage or fat. More

 Emerging Medical Technologies


A new frontier for wireless medical devices?
American Public Media    Share    Share on FacebookTwitterShare on LinkedinE-mail article
VideoBriefIt's only one agenda item at a meeting being held in Washington, D.C. That one item, however, may have an enormous effect on the future of medical treatment. The Federal Communications Commission is scheduled to vote on setting aside part of the broadcast spectrum for wireless medical devices. More

Inexpensive paper-based diabetes test developed
The Medical News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Scientists have developed a new, inexpensive and easy-to-use urine test for people with type 2 diabetes in areas of extreme poverty, such as rural India, China and other locations in the world. The paper-based device is described in the journal Analytical Chemistry, and could also be adapted to diagnose and monitor other conditions and the environment. More

 Managed Healthcare News


Report: For privately insured, doctors, surgery cost more in 2010
The Inquirer    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Higher prices for visits to doctors, surgery and drugs were the main cause of higher healthcare costs for privately insured Americans in 2010, when overall utilization of health-care services was down, a report by the Health Care Cost Institute in Washington said. More

Higher prices charged by hospitals, providers, drove health spending
Kaiser Health News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Higher prices charged by hospitals, outpatient centers and other providers drove up healthcare spending at double the rate of inflation during the economic downturn — even as patients consumed less medical care overall, according to a new study. More

 FDA: New Treatments and Technology


Takeda drug impresses in ulcerative colitis study
Reuters    Share    Share on FacebookTwitterShare on LinkedinE-mail article
More than 40 percent of patients with moderate to severe ulcerative colitis achieved clinical remission from the debilitating condition after a year of taking an experimental drug developed by Japan's Takeda Pharmaceutical, according to data from a pivotal late-stage trial. More

FDA reviewer recommends against Pfizer drug
The Wall Street Journal    Share    Share on FacebookTwitterShare on LinkedinE-mail article
A Food and Drug Administration medical reviewer recommended the agency not approve a drug developed by a Pfizer subsidiary to treat a rare genetic disorder that affects the nervous system because there's "inadequate" evidence the drug works. Pfizer subsidiary FoldRx is seeking FDA approval of a drug called tafamidis to treat an inherited condition called transthyretin familial amyloid polyneuropathy. More

FAST FACTS
"There are some risks to women undergoing hormone replacement therapy. Researchers have found healthy post-menopausal women were at increased risk of invasive breast cancer, coronary heart disease, stroke and blood clots, according to the National Institutes of Health."
 
Genomics Biotech and Emerging Medical Technologies Institute eBrief
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Christine Kraly, Content Editor, 469.420.2685   
Contribute news

This edition of the Genomics Biotech and Emerging Medical Technologies Institute eBrief was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!
Recent issues
May 24, 2012
May 17, 2012
May 10, 2012
May 3, 2012



7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063